In the journey to outperform the market, investors delve into the art of stock selection. Choosing the right stocks can be a powerful driver for wealth accumulation.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
As of close of business last night, CytomX Therapeutics Inc’s stock clocked out at $1.19, down -0.83% from its previous closing price of $1.20. In other words, the price has decreased by -$0.83 from its previous closing price. On the day, 0.5 million shares were traded. CTMX stock price reached its highest trading level at $1.2199 during the session, while it also had its lowest trading level at $1.16.
Ratios:
To gain a deeper understanding of CTMX’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.00 and its Current Ratio is at 1.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Piper Sandler on May 28, 2024, Upgraded its rating to Overweight and sets its target price to $3.50 from $2.25 previously.
On May 09, 2024, Wedbush Upgraded its rating to Outperform which previously was Neutral but kept the price unchanged to $8.
Jefferies Upgraded its Hold to Buy on May 06, 2024, whereas the target price for the stock was revised from $2.50 to $8.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Mar 19 ’24 when McCarthy Sean A. sold 20,223 shares for $2.09 per share. The transaction valued at 42,175 led to the insider holds 524,481 shares of the business.
BELVIN MARCIA sold 12,795 shares of CTMX for $26,684 on Mar 19 ’24. The SVP, Chief Scientific Officer now owns 168,579 shares after completing the transaction at $2.09 per share. On Mar 19 ’24, another insider, Landau Jeffrey B, who serves as the Chief Business Officer of the company, sold 6,562 shares for $2.09 each. As a result, the insider received 13,685 and left with 110,060 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CTMX now has a Market Capitalization of 93503304 and an Enterprise Value of -32476054. As of this moment, CytomX’s Price-to-Earnings (P/E) ratio for their current fiscal year is 8.54. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.78. Its current Enterprise Value per Revenue stands at -0.272 whereas that against EBITDA is -4.263.
Stock Price History:
Over the past 52 weeks, CTMX has reached a high of $5.85, while it has fallen to a 52-week low of $1.04. The 50-Day Moving Average of the stock is -14.99%, while the 200-Day Moving Average is calculated to be -29.96%.
Shares Statistics:
It appears that CTMX traded 1.85M shares on average per day over the past three months and 731740 shares per day over the past ten days. A total of 78.12M shares are outstanding, with a floating share count of 73.29M. Insiders hold about 6.17% of the company’s shares, while institutions hold 65.88% stake in the company. Shares short for CTMX as of 1721001600 were 7740177 with a Short Ratio of 4.18, compared to 1718323200 on 7758593. Therefore, it implies a Short% of Shares Outstanding of 7740177 and a Short% of Float of 10.0.
